More than 500 ounces of potentially contaminated marijuana — including some that tested positive for a fungus that can lead to lung infections or death — was quietly returned to store shelves in Michigan late last year, an MLive investigation revealed.
WeedLife News Network
“So, DMT vapes have now been patented,” Graham Pechenik, a San Francisco-based registered patent attorney, tweeted earlier this month.
Only it wasn’t a celebratory tweet. The application was filed in July 2020, and although vaping DMT, a hallucinogenic tryptamine drug, has been around for more than 10 years, the patent was granted earlier this month. A simple Google search could have revealed that, argues Pechenik.
“This is how patent trolls function,” Pechenik tells The GrowthOp’s Sam Riches following his Twitter post that sparked online outrage.
Graham Pechenik is a registered patent attorney and the founder of Calyx Law. Photo provided.
Psychedelics may find a smoother path toward federal legalization than cannabis has.
In this segment from Backstage Pass, recorded on Feb. 4, Motley Fool contributor Rachel Warren speaks with Tim Schlidt, co-founder and partner at psychedelic investment fund Palo Santo, about his work to help increase the supply of clinically effective and accessible mental health and addiction treatment solutions. Schlidt explains why he believes the pathway to federal legalization for psychedelics is much clearer than the approach cannabis is taking, for a multitude of reasons.
Rachel Warren: Psychedelic therapeutics, they are starting to gain broader recognition in the mainstream medical community. But at the same time, these treatments are still viewed by many with caution given their potential for abuse and even long-term negative outcomes in some cases. On the other hand, as we've been discussing, Wall Street seems to really be quite bullish about this space. This reminds me in some ways of how many investors have approached cannabis industry, which also as you mentioned faces a quasi legal landscape. I'm curious, do you think that the psychedelic therapeutics market could eventually outpace that of the cannabis market?
Tim Schlidt: I'm hesitant to say, it depends on how we define out pace, of course. I think from a market sizing standpoint, if cannabis could replace alcohol, the market potential there is very, very large. I will concede that point. Where I think this could certainly outpace cannabis is again from a regulatory perspective. I think the pathway to federal legalization is much, much better than the approach cannabis is taking for a multitude of reasons. That FDA pathway to DEA rescheduling I think is very superior. I forgot to mention earlier, we've seen a lot of case studies where this has occurred previously, be it Epidiolex, Marinol, Syndros, Xyrem, there's a lot of now-prescribed medications that were scheduled and got rescheduled upon FDA approval.
Also cannabis, even if you do achieve federal legalization, it's gone by such a state-by-state pathway that I think states are going to be hesitant to give up their tax revenue around cannabis. You're going to see this whole messy patchwork of state regulations versus federal regulations that you're just not dealing with that nearly as much here. It's a lot cleaner as a pathway. They will certainly outpace cannabis I think in terms of their timeline to market. We're seeing that already with maps advancing MDMA for PTSD, that will likely hit the market in 2023. Compass Pathways with psilocybin for treatment of resistant depression likely 2025 that that hits the market. It's within the next few years we could see psychedelics being prescribed for medical applications.
One other comment I'll make, just your comment on potential for abuse. I actually think psychedelics are much better than many known medications that are prescribed. Even we now know cannabis, there is some physical dependency around cannabis. With psychedelics, there's no physical dependency, at least for the classic psychedelics like an LSD, a mescaline, a psilocybin, since these are much more serotonin-based rather than dopamine-based, you don't really induce addictive behavior. Usually, any medications that activate your reward system, which is largely dopamine receptors and operating on those neurons, that's where you tend to see more abuse potential. We also know opioids as well, very potent opioid receptors.
New studies are showing how cannabinoids are helping patients with post-COVID recovery.
COVID-19 has taken countless lives worldwide, but thankfully with the vaccine, many have also been able to survive it.
However, surviving COVID-19 is not an easy feat. In many cases, the dreaded virus leaves damage in the bodies which we can feel for far long after we have tested negative. There are the usual symptoms such as dry cough, fever, colds, and shortness of breath.
The duration and severity of symptoms differs from one person to another, but there are also some people who will experience symptoms that will linger for a longer period of time. Depending on the case, the fatigue, shortness of breath, difficulty breathing, chest pains, stomach pains, brain fog, muscle pain, headaches, and heart palpitations among others.
When the symptoms persist for as long as 12 weeks after the infection, this is known as long COVID, and these conditions are not yet well understood. Doctors and researchers don’t know why it happens, who it will happen to, and how to prevent it. Of course, getting your vaccine helps reduce any complications, and a booster shot even if you have gotten COVID will also help. There is not much we can do to help treat it other than rest as much as you can, and for as long as it takes. Additionally, seeing your doctor to check for any complications will also help.
But what else can we do?
How Cannabis Can Aid In COVID Recovery
As we all know, the marijuana industry has grown substantially in recent years, with sales expected to hit $25 billion by 2025.
Revenue growth has been driven by more and more states legalizing the plant. In states like Illinois, cannabis sales pulled in nearly $1.4 billion in 2021, exceeding liquor taxes by nearly $100 million over the same period, after outpacing it for the first time in February. (article originally appeared on Benzinga)
However, with the plant still illegal under federal law – something that might change when/if Senate Majority Leader Chuck Schumer (D-N.Y.) and his colleagues file the long-awaited bill this April – conflict and ambiguity regarding the tax policy persist, creating "significant problems" for IRS and financial regulators, not to mention cannabis operators and companies.
With tax season upon us, confusion over whether medical marijuana is tax-deductible has come up, writes Marijuana Moment.
In an interview with C-SPAN's Washington Journal, IRS taxpayer advocate Erin Collins was asked by a caller from Nevada, where cannabis is fully legal, why he couldn't find an option on TurboTax to deduct his cannabis purchases!
Collins, appointed during the Trump administration, said she'd have to "plead ignorance on the marijuana" question "unless you're saying it's a medical deduction.
Should terminal patients be able to get cannabis while at the hospital or hospice?
Even in states where cannabis has been legalized for medical use, patients struggle to find the information that they need when it comes to using cannabis as medicine.
There’s tons of questions that overwhelm patients: how much cannabis to use, what method of administration is best, how often to take it, and so much more. Given these circumstances, most patients are left to their own devices when it comes to deciding how to use cannabis. And even then, doctors still don’t feel that they are equipped with the right knowledge to prescribe cannabis as a medication or part of their therapy.
Having said that, we are severely limiting the impact cannabis could have on the lives of patients, especially those who are terminally ill. There is already an astounding body of evidence that cannabis can make life more manageable for those with cancer, struggling through chemotherapy and radiation, Parkinson’s Disease, and so much more.
So why can’t patients be given cannabis medications in the hospital, supervised the way they are with conventional medications?
California Is A Pioneer
In December 2021, California Governor Gavin Newsom made waves by signing a legislation from Senator Ben Hueso that would offer more choices for end-of-life options for locals with the requirement that certain healthcare facilities and hospitals would allow terminally-ill patients to use medical marijuana for pain relief or as part of their treatment.
The Legislature can and should end this harmful discrimination against qualified patients and dispensaries.
It is curious to see the recent dispensary complaints about restrictive regulation and unsustainable tax burdens.
What is missing from this discussion is the fact that Hawaii’s eight dispensaries — as well as our 34,000 lawfully registered medical cannabis patients, for that matter — are all technically federal criminals because the mere possession of cannabis without formal authorization from the Drug Enforcement Administration is a violation of federal law and the federal regulation of marijuana.
The problems that the dispensaries are describing are almost entirely due to the consequences of being continuing criminal enterprises and drug traffickers in the eyes of the federal government, which prohibits the dispensaries from utilizing regular banking services or deducting standard business expenses from their federal tax returns, resulting in an exorbitant federal tax burden of about 70% that must be paid in cash.
This should make us all wonder why the dispensaries are not screaming bloody murder to do something about ending the 22-year-old conflict between the state-authorized medical use of cannabis and the federal regulation of marijuana.
Licensed medical cannabis dispensaries are well established in the islands. But patient and dispensary rights are at risk. Anthony Quintano/Civil Beat/2017
Scottish epilepsy patients as young as two could be given new cannabis-based medication today approved for use on the NHS.
Health bosses have given the green light to Epidyolex, which can help treat the symptoms of a rare genetic disease affecting around one in 10,000 people.
Tuberous sclerosis complex (TSC) causes tumours to grow in the body and around 80% of patients develop epilepsy from it, typically in their first year of life.
Additionally, for the majority of people, their condition doesn’t respond to standard anti-seizure medication – making today’s Scottish Medical Consortium decision a potential game-changer.
Scotland has become the second UK nation to approve the oral solution for use, following Wales.
Medication ‘desperately needed’ for families
Louise Fish, the chief executive of the Tuberous Sclerosis Association, says life could now be very different for those with the debilitating condition.
A long-term study tracking just over a thousand participants has found regular cannabis smoking can change the function of your lungs as you age. Unlike smoking a cigarette, however, cannabis seems to impact a person's breathing in a slightly different way.
Ultimately, the authors found both changes lead to similar end results – constricting airways and leading to hyperinflation and gas trapping.
These patterns of lung function match previous results from the same cohort, which were collected 13 years earlier when the participants were 32 years of age.
"Although the effects of cannabis were detrimental, the pattern of lung function changes was not the same," says respiratory specialist Bob Hancox from the University of Otago in New Zealand.
"The research found that prolonged cannabis use led to over-inflated lungs and increased the resistance to airflow to a greater extent than tobacco."
Cannabis consumers who had used the drug 11 to 100 times or more were four to five years younger “when they developed cataracts than subjects who never used cannabis.”
Researchers were not surprised by their recent findings, but argue added study is needed to determine if cannabis smoking, like cigarette smoking, is a risk factor for developing cataracts.
“Like tobacco smoke, cannabis smoke contains thousands of organic and inorganic chemical compounds,” U.S. investigators write in the study, published on Jan. 31 in the Journal Français d’Ophtalmologie.
In the new study, the authors point out that cannabis tar is chemically similar to tobacco smoke tar. That, coupled with the fact that more than 50 known carcinogens have been identified in cannabis tar, means “the association of cannabis with cataracts that we report here is not entirely surprising.”
To get a firmer grasp of the association, if any, researchers at the Icahn School of Medicine at Mount Sinai and at Severn Health Solutions analyzed data from the U.K. Biobank, a large-scale biomedical database and research resource, containing genetic and health information from half a million U.K. participants.
All subjects had cataracts and their tobacco/cannabis habits were known. Those who had ever smoked cannabis were included as part of the study group.
Even though melatonin is an over-the-counter medicine, not enough is known about it for people to be consuming it so comfortably.
Sleep disorders are incredibly common, affecting about 70 million Americans a year. Medications and other substances that treat sleep are increasingly common, although with some concerning side effects that might impact sleep in the long term.
One of the most harmless solutions to this is melatonin, a compound that’s been growing in popularity over the years. Still, when used at high levels, it has a certain amount of risks.
According to a new study, melatonin use has increased over the past few years, increasing by more than twice the amount consumed a decade ago.
According to the NIH, melatonin has been linked with headaches, dizziness, nausea, irritability, anxiety and depression, and is capable of interacting with other medications. “We cannot be certain of the purity of melatonin that is available over the counter,” sleep specialist Rebecca Robbins told CNN.
While it appears that in the short term melatonin provides useful benefits, its long-term use is much more complex than a harmless pill that can put you to bed.
The benefits of CBD as well as adaptogens clearly fill a massive void in western medicine so it’s not surprising to see patients fall for their charms.
Cannabidiol (CBD) may seem like it’s been a hot topic on the wellness front for quite some time now. After all, the non-psychoactive compound of marijuana has touted for its stress and anxiety-relieving properties without getting you high. It has a cult following, and for good reason — there’s a lot of data and evidence that CBD does work. It’s everywhere these days, from CBD capsules to oils, beverages and edibles, getting rid of stress has never been easier.
But sharing the limelight with CBD these days are adaptogens.
Adaptogens have been known for hundreds of years, especially in Asia and India, and among those who follow Ayurvedic lifestyle principles. They refer to types of plants that possess special properties to help the body cope with stress, regulate healthy functioning and hormonal balance. Aside from that, they have numerous other health benefits such as help fighting off fatigue, reduce inflammation, improve sleep, and improve cognitive function even when we are under periods of stress among others.
Benefits of Combining CBD and Adaptogens
Popular and common adaptogens that you’ll easily encounter in the market are the following:
Ashwagandha: Widely used for centuries to treat stress and anxiety, and its use in ayurvedic potions. Ashwagandha is a root that is also used in some eastern delicacies.
Women who smoke cannabis during pregnancy double the risk of stunting their baby’s growth, a study warns.
Risks of premature birth, lower birth weight and possible low intelligence in later life were all increased. The report came from data on 60,000 mothers in the US, Canada and Jamaica in 16 studies. Chances of newborns being small for their age rose by 61 per cent for cannabis users. And the risk of being born premature went up by 28 per cent. Scores given to newborns that assess pulse, breathing and reactions also fell by 26 per cent, the Marchand Institute for Minimally Invasive Surgery, US, found. Dr Greg Marchand said: “Women exposed to marijuana in pregnancy were at a significantly increased risk of adverse neonatal outcomes.
“Given increasing marijuana legalisation and use worldwide, raising awareness and educating patients about these adverse outcomes may help to improve neonatal health.”
Some people with Parkinson’s disease find that using cannabis products helps to ease certain symptoms, according to results from a survey.
The findings notably suggest that cannabis products with high levels of the chemical THC are more likely to induce both positive and negative effects in Parkinson’s patients.
“These survey results offer a broad overview of real-world cannabis use patterns and experience among a large group of people living with [Parkinson’s] and provide initial results regarding the differential symptomatic effects of” different cannabis products, researchers wrote.
Findings were published in the study, “Higher risk, higher reward? Self-reported effects of real-world cannabis use in Parkinson’s disease,” in Movement Disorders.
Cannabis has two main active components: tetrahydrocannabinol (THC), which is the main chemical that induces a “high,” and cannabidiol (CBD), which doesn’t induce a “high” but may have numbing or anti-inflammatory properties.
This expands the eligibility criteria for patients who can benefit from medical cannabis and makes it easier for them to be certified by a medical practitioner.
A new Medical Cannabis Program certification and registration system went into effect on Monday across the state.
This expands the eligibility criteria for patients who can benefit from medical cannabis and makes it easier for them to be certified by a medical practitioner.
Last year's marijuana regulation and taxation act ensured that this new system will be run by the office of cannabis management instead of the health department.
The program was first proposed back in October.
Patients who are certified through the new certification and registration system will be issued a new certification from the New York State Office of Cannabis Management after the current one expires.
Responsible parties should inform consumers, especially teens, about the harms of cannabis and the serious conditions that may arise from abusing the substance.
One of marijuana’s most concerning connections is the one it has with psychosis. While not wholly understood, this link has been reported to be significant, with several studies indicating that people who smoke large amounts of weed on a daily basis are five times more likely to develop psychosis than others. This depends on the age at which marijuana is first consumed and the individual’s genetic vulnerabilities.
New studies: Survey of user experience and warnings of unregulated contaminants.
The sudden appearance of delta-8-tetrahydrocannabinol (delta-8-THC, or delta-8) and its quick rise in popularity is a classic tale of unintended consequences and loopholes that enterprising entrepreneurs rush through.
1. Delta-8 is a cannabinoid molecule naturally found in cannabis.
The cannabis plant contains over 100 similar molecules called cannabinoids, most of them in small quantities and with unknown properties. Delta-9-tetrahydrocannabinol, commonly called THC, is the most abundant and most psychoactive molecule in popular strains of marijuana. When the double bond between two carbon atoms shifts location slightly, it creates delta-8, which has similar effects as delta-9 but is only two-thirds as strong. Until recently, delta-8 was little known because cannabis plants contain only .1 percent delta-8, which is too little to extract profitably.
2. Delta-8 is legal and unregulated.
The 2018 Farm Bill legalized industrial hemp products as long as the delta-9 content remained below .3 percent. This bill permitted a great increase in the production of CBD (cannabidiol), which exists in sufficient amounts in hemp to be extracted profitably. When over-production of CBD created a glut that plummeted prices in 2020, the industry began looking for innovative ways to make the excess CBD profitable. Simple chemistry discovered in the 1960s using solvents like toluene began being used to convert CBD into delta-8.
Since the Farm Bill said nothing specific about delta-8, it remained legal federally, and only 14 states have restricted its sale to date. Able to be offered on the Internet, mailed through the US Postal Service, and sold in gas stations, convenience stores, and cannabis dispensaries, it has been the fastest-growing segment of the hemp-derived market this last year, says Ian Laird of data analytics company Hemp Benchmarks.
The hemp industry has been unloading products containing new alternative cannabinoids targeting specific moods and providing more benefits. One of the cannabinoids increasing in popularity is called CBN (Cannabinol), also known as the CBD for sleep.
CBN is a cannabinoid found in, and derived from, the hemp plant. Although close in chemical structure to CBD, the compounds produce very different results. CBN is specifically for getting to sleep, staying asleep and for anti-anxiety.
What is CBN?
Cannabinol, the scientific name for CBN, has been the newest upcoming cannabinoid and consumers have been flocking to it due to its sleep and relaxing properties.
CBN is created naturally due to the degradation of Delta 9 THC. Because of the technology that hemp companies have been able to scale, this magical cannabinoid can now be adopted at scale by consumers.
What is the difference between CBN and CBD?
Due to the fact that the hemp industry is discovering more potent benefits the alternative cannabinoids are offering, CBD has been slowly fading out into the background due to its lack of strength in benefits compared to CBN and others.
An expansion to Utah's medical cannabis program has officially launched, allowing more health care workers to recommend marijuana to qualifying patients.
The program allows any licensed physician, physician's assistant, nurse or podiatrist with a controlled substance license to recommend cannabis to up to 15 patients. There are more than 21,000 medical providers who can now recommend medical cannabis, the Utah Department of Health said.
"This program expands access to medical cannabis for qualifying patients by increasing the number of clinicians who have the option to recommend medical cannabis. In the past, adult patients had to obtain a recommendation from one of the 800 medical providers who were registered with the Utah Department of Health but that is no longer the case," Richard Oborn, Utah Department of Health's Center for Medical Cannabis director, said in a statement.
FOX 13 first reported in 2019 about problems qualifying patients were having getting a physician willing to recommend. The Utah State Legislature created the "limited medical provider" option to get health care workers more comfortable with cannabis.
The expansion was supposed to launch last October, but staffing and technology issues delayed it. Lawmakers, caught off guard by the delay, were not pleased and demanded timelines be sped up. Patient advocates were also frustrated.
Marijuana edibles are becoming increasingly popular, but doctors warn the substances are prone to accidental consumption or may pack too much of a wallop for new users.
Newly released numbers show marijuana overdose-related calls in Illinois jumped significantly after legalization, mainly due to edibles — but remained far below the number of calls for other legal drugs, including alcohol.
The number of calls to the Illinois Poison Center for cannabis rose from 487 in 2019, to 743 in 2020, the year recreational weed was legalized in the state, and increased again to 855 in 2021.
Many of the calls were for consumption of edibles, officials said. Edible cases more than tripled from 80 cases in 2019 to 450 in 2021.
Many of the calls are for children. Calls to the poison center increased for children 5 and under from 81 in 2019, to 278 in 2021.